Successful Control of Malignant Pericardial Effusion from Endometrial Cancer Using Intrapericardial Chemotherapy: A Case Report
Main Article Content
Abstract
Endometrial cancer (EC) is one of the most common gynecologic malignancies worldwide, with increasing incidence and mortality. Although metastasis typically involves lymph nodes, peritoneum, and lungs, malignant pericardial effusion (MPE) is a rare and life-threatening complication, often associated with advanced disease and poor prognosis. We report the case of a 70-year-old woman with stage IIIB endometrial adenocarcinoma previously treated with surgery, chemotherapy, and radiotherapy, who presented three years later with cardiac tamponade due to MPE. Initial management with pericardiocentesis resulted in clinical stabilization; however, early recurrence occurred within 30 days, with cytological and histopathological confirmation of metastatic carcinoma of Müllerian origin. Given the high risk of recurrence, intrapericardial chemotherapy with cisplatin was administered (10 mg/20 mL daily for five days) via a pericardial catheter. The patient tolerated the procedure well, with no significant complications or systemic toxicity. Follow-up echocardiography demonstrated complete resolution of the effusion, and the patient remained asymptomatic at one-month follow-up, without evidence of early recurrence. This case highlights the feasibility and effectiveness of intrapericardial cisplatin as a locoregional treatment strategy for recurrent MPE in selected patients. Although evidence is limited and primarily derived from observational studies, this approach may reduce recurrence rates and the need for repeated invasive procedures. Intrapericardial chemotherapy should be considered within a multidisciplinary framework, particularly in palliative settings where local control is the primary goal.
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their articles and grant the journal the right of first publication under the Creative Commons Attribution (CC BY) license, which allows others to share and adapt the work with proper attribution.
References
World Cancer Research Fund. Endometrial cancer statistics [Internet]. [cited 2026 Mar 5]. Available from: https://www.wcrf.org/preventing-cancer/cancer-statistics/endometrial-cancer-statistics/
National Cancer Institute (US). Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: uterine cancer [Internet]. Bethesda (MD): National Cancer Institute; [cited 2026 Mar 5]. Available from: https://seer.cancer.gov/statfacts/html/corp.html
American Cancer Society. Key statistics for endometrial cancer [Internet]. Atlanta: American Cancer Society; [cited 2026 Mar 5]. Available from: https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.html
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Ann Oncol. 2021;32(9):1089-1100.
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma [Internet]. European Society of Gynaecological Oncology; 2025 [cited 2026 Mar 5]. Available from: https://guidelines.esgo.org/media/2025/09/ESGO-ESTRO-ESP-Guidelines-for-EC_-LO-July-2025.pdf
Zhai Y, et al. Malignant pericardial effusion in cancer patients: current perspectives and management. Cancers (Basel). 2024;16(20):3466.
Mori M, et al. Management strategies for malignant pericardial effusion in cancer patients. JACC CardioOncol. 2024.
International Agency for Research on Cancer. Corpus uteri fact sheet [Internet]. Lyon: IARC; 2022 [cited 2026 Mar 5]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/24-corpus-uteri-fact-sheet.pdf
American Cancer Society. Survival rates for endometrial cancer [Internet]. Atlanta: American Cancer Society; [cited 2026 Mar 5]. Available from: https://www.cancer.org/cancer/types/endometrial-cancer/detection-diagnosis-staging/survival-rates.html
Schulz-Menger J, et al. Malignant pericardial effusion: contemporary management and outcomes. Cardiooncology. 2024;10:207.
Mori M, et al. Intrapericardial cisplatin for malignant pericardial effusion: outcomes and recurrence rates. Curr Oncol. 2025;32(10):568.
Klein AL, et al. Percutaneous approach to pericardial disease management. Curr Cardiol Rep. 2023.
Adler Y, et al. Advances in the diagnosis and management of pericardial diseases. J Clin Med. 2025;15(1):83.
Schulz-Menger J, et al. Cardio-oncology considerations in malignant pericardial disease. CJC Open. 2024.
Liu H, et al. Diagnostic performance of pericardial fluid cytology in malignant pericardial effusion. Diagnostics (Basel). 2022;12(2):367.
Schulz-Menger J, et al. Management of malignant pericardial effusion in oncology patients. CJC Open. 2024.
Mori M, et al. Intrapericardial cisplatin for recurrent malignant pericardial effusion: a cohort study. Curr Oncol. 2025.
Adler Y, et al. 2025 ESC guidelines for the management of pericardial diseases. Eur Heart J. 2025;46(40):3952-4013.
Patel N, et al. Malignant pericardial effusion secondary to gynecologic malignancy: case report and review. Clin Case Rep. 2020;8:e30919.
Li X, et al. Management strategies and outcomes of malignant pericardial effusion in thoracic oncology. J Cardiothorac Surg. 2025.